In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to determine Safe and sound dosing program. Further members will probably be enrolled for the discovered monotherapy dosign regimen. In Segment B, members will acquire oral ruxolitinib and ABBV-744 will likely be supplied as "increase-on" therapy. https://abbv-744therapeuticpotent34689.myparisblog.com/32467398/brd4-targeted-therapy-abbv-744-clinical-data-no-further-a-mystery